Carl Deutsch serves as Chief Scientific Officer (CSO) at NBE Therapeutics since September 1st, 2022.
Carl has over a decade experience in drug discovery for small molecules and especially Antibody Drug Conjugates (ADCs) in Oncology, Immuno-Oncology, and Immunology.
He started his career in Medicinal Chemistry at Merck KGaA before he joined its newly formed ADC Department, leading ADC Chemistry as well as, subsequently, Cell-Biology.
One major contribution by him and his team was the discovery and optimization of several novel linker payload platforms of which one became part of the clinical ADC M9140, currently in Phase 1 trials.
Additionally, he was one of the inventors and research lead of the award winning technology Chetosensartm , a carbohydrate-based ADC solubility enhancer, launched by Millipore-Sigma in 2022.
Carl holds a PhD in Chemistry from TU Dortmund (Prof. N. Krause) and an executive MBA from MBS Mannheim / ESSEC Paris.
Moreover, he was visiting scientists at UCSB Santa Barbara (Prof. B. Lipshutz, USA) and Kyoto University (Prof. M. Murakami, Japan) and worked as a Post Doc with Prof. P. Wipf (Pittsburgh University, USA).